REGN — Regeneron Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- $98.44bn
- $90.29bn
- $13.12bn
- 94
- 32
- 88
- 82
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,214 | 3,587 | 5,695 | 7,742 | 10,845 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,672 | 4,115 | 6,037 | 5,329 | 5,667 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 7,689 | 9,779 | 14,015 | 15,884 | 19,479 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2,890 | 3,222 | 3,482 | 3,763 | 4,224 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 14,805 | 17,163 | 25,435 | 29,215 | 33,080 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2,097 | 2,697 | 3,933 | 3,141 | 3,423 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3,716 | 6,138 | 6,666 | 6,551 | 7,107 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 11,090 | 11,025 | 18,769 | 22,664 | 25,973 |
Total Liabilities & Shareholders' Equity | 14,805 | 17,163 | 25,435 | 29,215 | 33,080 |
Total Common Shares Outstanding |